Mitochondrial therapies for Parkinson's disease

Bobby Thomas, M. Flint Beal

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Parkinson's disease (PD) is marked by widespread neurodegeneration in the brain in addition to a selective yet prominent and progressive loss of nigrostriatal dopaminergic neurons. Of the multiple theories suggested in the pathogenesis of PD, mitochondrial dysfunction takes a center stage in both sporadic and familial forms of illness. Deficits in mitochondrial functions due to impaired bioenergetics, aging associated increased generation of reactive oxygen species, damage to mitochondrial DNA, impaired calcium buffering, and alterations in mitochondrial morphology may contribute to improper functioning of the CNS leading to neurodegeneration. These mitochondrial alterations suggest that a potential target worth exploring for neuroprotective therapies are the ones that can preserve mitochondrial functions in PD. Here, we provide a recent update on potential drugs that are known to block mitochondrial dysfunctions in various experimental models and those that are currently under clinical trials for PD. We also review novel mitochondrial survival pathways that provide hope and promise for innovative neuroprotective therapies in the future that can be explored as possible therapeutic intervention for PD pathogenesis.

Original languageEnglish (US)
JournalMovement Disorders
Volume25
Issue numberSUPPL. 1
DOIs
StatePublished - Dec 20 2010

Fingerprint

Parkinson Disease
Investigational Therapies
Dopaminergic Neurons
Therapeutics
Mitochondrial DNA
Energy Metabolism
Reactive Oxygen Species
Theoretical Models
Clinical Trials
Calcium
Mitochondrial Parkinson Disease
Brain
Pharmaceutical Preparations

Keywords

  • Coenzyme Q10
  • Creatine
  • Mitochondrial dysfunction
  • PGC-1α
  • Parkinson's disease
  • Sirtuins

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Mitochondrial therapies for Parkinson's disease. / Thomas, Bobby; Beal, M. Flint.

In: Movement Disorders, Vol. 25, No. SUPPL. 1, 20.12.2010.

Research output: Contribution to journalArticle

Thomas, Bobby ; Beal, M. Flint. / Mitochondrial therapies for Parkinson's disease. In: Movement Disorders. 2010 ; Vol. 25, No. SUPPL. 1.
@article{f7ed11bba8a049ecac0e59db608739db,
title = "Mitochondrial therapies for Parkinson's disease",
abstract = "Parkinson's disease (PD) is marked by widespread neurodegeneration in the brain in addition to a selective yet prominent and progressive loss of nigrostriatal dopaminergic neurons. Of the multiple theories suggested in the pathogenesis of PD, mitochondrial dysfunction takes a center stage in both sporadic and familial forms of illness. Deficits in mitochondrial functions due to impaired bioenergetics, aging associated increased generation of reactive oxygen species, damage to mitochondrial DNA, impaired calcium buffering, and alterations in mitochondrial morphology may contribute to improper functioning of the CNS leading to neurodegeneration. These mitochondrial alterations suggest that a potential target worth exploring for neuroprotective therapies are the ones that can preserve mitochondrial functions in PD. Here, we provide a recent update on potential drugs that are known to block mitochondrial dysfunctions in various experimental models and those that are currently under clinical trials for PD. We also review novel mitochondrial survival pathways that provide hope and promise for innovative neuroprotective therapies in the future that can be explored as possible therapeutic intervention for PD pathogenesis.",
keywords = "Coenzyme Q10, Creatine, Mitochondrial dysfunction, PGC-1α, Parkinson's disease, Sirtuins",
author = "Bobby Thomas and Beal, {M. Flint}",
year = "2010",
month = "12",
day = "20",
doi = "10.1002/mds.22781",
language = "English (US)",
volume = "25",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Mitochondrial therapies for Parkinson's disease

AU - Thomas, Bobby

AU - Beal, M. Flint

PY - 2010/12/20

Y1 - 2010/12/20

N2 - Parkinson's disease (PD) is marked by widespread neurodegeneration in the brain in addition to a selective yet prominent and progressive loss of nigrostriatal dopaminergic neurons. Of the multiple theories suggested in the pathogenesis of PD, mitochondrial dysfunction takes a center stage in both sporadic and familial forms of illness. Deficits in mitochondrial functions due to impaired bioenergetics, aging associated increased generation of reactive oxygen species, damage to mitochondrial DNA, impaired calcium buffering, and alterations in mitochondrial morphology may contribute to improper functioning of the CNS leading to neurodegeneration. These mitochondrial alterations suggest that a potential target worth exploring for neuroprotective therapies are the ones that can preserve mitochondrial functions in PD. Here, we provide a recent update on potential drugs that are known to block mitochondrial dysfunctions in various experimental models and those that are currently under clinical trials for PD. We also review novel mitochondrial survival pathways that provide hope and promise for innovative neuroprotective therapies in the future that can be explored as possible therapeutic intervention for PD pathogenesis.

AB - Parkinson's disease (PD) is marked by widespread neurodegeneration in the brain in addition to a selective yet prominent and progressive loss of nigrostriatal dopaminergic neurons. Of the multiple theories suggested in the pathogenesis of PD, mitochondrial dysfunction takes a center stage in both sporadic and familial forms of illness. Deficits in mitochondrial functions due to impaired bioenergetics, aging associated increased generation of reactive oxygen species, damage to mitochondrial DNA, impaired calcium buffering, and alterations in mitochondrial morphology may contribute to improper functioning of the CNS leading to neurodegeneration. These mitochondrial alterations suggest that a potential target worth exploring for neuroprotective therapies are the ones that can preserve mitochondrial functions in PD. Here, we provide a recent update on potential drugs that are known to block mitochondrial dysfunctions in various experimental models and those that are currently under clinical trials for PD. We also review novel mitochondrial survival pathways that provide hope and promise for innovative neuroprotective therapies in the future that can be explored as possible therapeutic intervention for PD pathogenesis.

KW - Coenzyme Q10

KW - Creatine

KW - Mitochondrial dysfunction

KW - PGC-1α

KW - Parkinson's disease

KW - Sirtuins

UR - http://www.scopus.com/inward/record.url?scp=77953425159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953425159&partnerID=8YFLogxK

U2 - 10.1002/mds.22781

DO - 10.1002/mds.22781

M3 - Article

VL - 25

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - SUPPL. 1

ER -